Janux Other Operating Expenses vs Total Other Income Expense Net Analysis
| JANX Stock | USD 48.82 1.49 2.96% |
Janux Therapeutics financial indicator trend analysis is infinitely more than just investigating Janux Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Janux Therapeutics is a good investment. Please check the relationship between Janux Therapeutics Other Operating Expenses and its Total Other Income Expense Net accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Janux Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Janux Stock please use our How to Invest in Janux Therapeutics guide.
Other Operating Expenses vs Total Other Income Expense Net
Other Operating Expenses vs Total Other Income Expense Net Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Janux Therapeutics Other Operating Expenses account and Total Other Income Expense Net. At this time, the significance of the direction appears to have strong relationship.
The correlation between Janux Therapeutics' Other Operating Expenses and Total Other Income Expense Net is 0.77. Overlapping area represents the amount of variation of Other Operating Expenses that can explain the historical movement of Total Other Income Expense Net in the same time period over historical financial statements of Janux Therapeutics, assuming nothing else is changed. The correlation between historical values of Janux Therapeutics' Other Operating Expenses and Total Other Income Expense Net is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Operating Expenses of Janux Therapeutics are associated (or correlated) with its Total Other Income Expense Net. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Other Income Expense Net has no effect on the direction of Other Operating Expenses i.e., Janux Therapeutics' Other Operating Expenses and Total Other Income Expense Net go up and down completely randomly.
Correlation Coefficient | 0.77 |
| Relationship Direction | Positive |
| Relationship Strength | Significant |
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Janux Therapeutics. It is also known as Janux Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Other Income Expense Net
Most indicators from Janux Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Janux Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Janux Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Janux Stock please use our How to Invest in Janux Therapeutics guide.At this time, Janux Therapeutics' Issuance Of Capital Stock is fairly stable compared to the past year. Enterprise Value is likely to rise to about 850.2 M in 2024, whereas Selling General Administrative is likely to drop slightly above 13.5 M in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 370K | 4.0M | 4.6M | 4.9M | Depreciation And Amortization | 113K | 841K | 2.0M | 2.1M |
Janux Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Janux Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Janux Stock Analysis
When running Janux Therapeutics' price analysis, check to measure Janux Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Janux Therapeutics is operating at the current time. Most of Janux Therapeutics' value examination focuses on studying past and present price action to predict the probability of Janux Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Janux Therapeutics' price. Additionally, you may evaluate how the addition of Janux Therapeutics to your portfolios can decrease your overall portfolio volatility.